Found 8 matching trials
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff PHASE3 The purpose of this study is to evaluate whether LY3819253 given alone and ...
Show More Location
Unv of AL Sch of Med Div of Infectious Diseases
Learn More & Join Trial
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB) N/A Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine respons...
Show More Location
Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital
Learn More & Join Trial
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness PHASE2 The purpose of this study is to measure how well LY3819253 and LY3832479 wo...
Show More Location
Clinnova Research - Redondo Beach
Learn More & Join Trial
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness PHASE2 The purpose of this study is to measure how well monoclonal antibodies work...
Show More Location
University of Alabama at Birmingham
Learn More & Join Trial
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 N/A This is a national multicentre observational study with retrospective and p...
Show More Location
Asst-Monza Ospedale San Gerardo
Learn More & Join Trial
Non-inferiority Trial on Monoclonal Antibodies in COVID-19 PHASE3 Currently, 3 anti-SARS-CoV-2 monoclonal antibody products have received Eme...
Show More Location
IRCCS Policlinico di S. Orsola
Learn More & Join Trial
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort. N/A This is a prospective, multicentric, non comparative study aiming to evalua...
Show More Learn More & Join Trial
UPMC OPTIMISE-C19 Trial, a COVID-19 Study PHASE4 Multiple monoclonal antibodies (mABs) have been shown to reduce viral burde...
Show More Learn More & Join Trial